Clin Cancer Res: The efficacy and safety of the new anti-PD-L1 antibody LY3300054 for the treatment of advanced solid tumors

High-expression procedural cell death lilogy protein 1 (PD-L1) is one of the mechanisms of tumor cell escape anti-tumor immune response.
blocking PD-L1 or its corresponding subject PD-1 can reactivate cytotoxic T-cell reactions, which in turn can cause multiple tumors to subside.
A Phase Ia/Ib PACT study (NCT02791334) evaluated a new PD-L1 inhibitor LY3300054 as a monotherapy or in combination with Remolu monoantigen, Abemaciclib, or Merestinib (a type II MET kinase inhibitor) to treat the safety, pharmacodynamics, pharmacological and anti-tumor activity of late-stage refractic solid tumors.
the results of this study are reported in this paper.
patients who received LY3300054 monotherapy or combined reed monotherapy, Abemaciclib or Merestinib were 15, 10, 24, and 12 in the IA phase LY3300054 dose incremental queue.
expanded the dose queue during phase IB, including 8 melanoma patients receiving LY330054 single treatment and 12 pancreatic cancer patients receiving LY3300054 combined Meestinib treatment.
end points are dose-limiting toxicity (DLT) and safety.
treatment-related adverse reactions were fatigue and nausea in the single treatment group (13 per cent each), hypothyroidation in the Remo reed monoantigen group (30 per cent), diarrhea in the Abemaciclib group (54 per cent), and nausea in the Merestinib group (25 per cent).
DLT associated with liver toxicity was observed in 3 of the 4 patients introduced into the queue at Abemaciclib.
but no DLT or 3/4 hepatotoxicity events were observed in patients who were taking Abemaciclib at the same time.
pharmacodynamic characteristics are similar to other PD-L1 inhibitors.
, according to RECISTV 1.1, 1 patient in each group received partial remission for up to 7 months.
, the LY3300054 is used alone or in federation with Remo Reed Monoanti, Abemaciclib, or Merestinib, and the tolerance is good and there are no unexpected safety issues.
because of Abemaciclib's liver toxicity, it cannot be used immediately before it is used in association with LY3300054.
of the options presented for this assessment demonstrates lasting clinical benefits.